Targeting delivery of tumor-associated carbohydrate antigen(TACA)-based vaccine to antigen-presenting cells(APCs)mediated by endogenous antibodies can improve the immunogenicity of TACA.However,an essential requiremen...Targeting delivery of tumor-associated carbohydrate antigen(TACA)-based vaccine to antigen-presenting cells(APCs)mediated by endogenous antibodies can improve the immunogenicity of TACA.However,an essential requirement of this approach is to generate high titers of endogenous antibodies in vivo through pre-immunization,which complicates the immunization procedure and may cause side effects.Herein,we report a new generation of APC-targeting TACA-based supramolecular complex vaccine,assembled by sialyl Thomsen-nouveau-bovine serum albumin-adamantine(sTn-BSA-Ada)and heptavalent rhamnose(Rha)-modifiedβ-cyclodextrin(β-CD)via host-vip interaction.The complex vaccine retained anti-Rha antibodies recruiting capability and facilitated the APCs uptake of the vaccine via the interaction of the Fc-domain with the Fc receptors on APCs.We demonstrate that direct immunization of complex vaccine elicited anti-Rha and anti-sTn specific immune response synchronously,generating a novel self-enhancement effect that can improve the antigen delivery to APCs in high efficacy.The structure-activity relationship(SAR)study proved that complex vaccine 4 with polyethylene glycol 6(PEG 6)linker in host molecule provoked a robust and specific sTn immune response comparable to the pre-immunization approach.The antisera induced by complex vaccine,either through direct immunization or pre-immunization,exhibited equal potency of cytotoxicity against the sTn expression cancer cells.This study provides a general platform for TACA-based vaccines with self-enhancement effects without the need for pre-immunization.展开更多
We construct MUC1 vaccines usingβ-cyclodextrin grafted chitosan(CS-g-CD)as carrier via host-vip interaction.These vaccines based on non-covalent assembling can provoke robust immune responses,including high level o...We construct MUC1 vaccines usingβ-cyclodextrin grafted chitosan(CS-g-CD)as carrier via host-vip interaction.These vaccines based on non-covalent assembling can provoke robust immune responses,including high level of specific antibodies and cytokines.The induced antibodies can specifically recognize tumor cells and mediate cytotoxicity against tumor cells.These results indicate that CS-g-CD with strong immunostimulatory activities can be a straightforward platform for peptide-based vaccine construction.展开更多
Staphylococcus aureus wall teichoic acids(WTAs) are attractive targets for antibacterial vaccine development. In this study, three core glycosylated WTA structure, including α-1,4-Glc NAc, β-1,4-Glc NAc andβ-1,3-Gl...Staphylococcus aureus wall teichoic acids(WTAs) are attractive targets for antibacterial vaccine development. In this study, three core glycosylated WTA structure, including α-1,4-Glc NAc, β-1,4-Glc NAc andβ-1,3-Glc NAc modified ribitol phosphates containing a linker are chemically synthesized and conjugated with tetanus toxin(TT) carrier protein as vaccine candidates. In vivo immunological studies demonstrate that the synthesized glycosylated WTAs display high immunogenicity and all conjugates provoke strong immune responses and elicit high levels of specific IgG antibodies against the Glc NAc-modified WTA. Furthermore, antibodies elicited by the vaccine candidates remain the capability to recognize S. aureus cells and display significant opsonophagocytic activity to clear S. aureus. This study demonstrates that the core structure of glycosylated WTAs are effective antigens for constructing anti-S. aureus vaccines to prevent and control S. aureus infections.展开更多
Tumor-associated carbohydrate antigens(TACAs) are attractive targets for vaccine development. In this context, we described a strategy combining artificial TACA and glycoengineering for cancer vaccine development. A 2...Tumor-associated carbohydrate antigens(TACAs) are attractive targets for vaccine development. In this context, we described a strategy combining artificial TACA and glycoengineering for cancer vaccine development. A 2,4-ditrophenyl(DNP)-modified GM3 intermediate was synthesized chemoenzymatically and conjugated to keyhole limpet hemocyanin(KLH), and the resulting bioconjugate was tested for its potential as a vaccine candidate. Mice immunological studies revealed that the DNP-modified GM3(GM3-NHDNP) analog elicited strong and rapid immune responses by recruiting anti-DNP antibodies to facilitate the targeted delivery of the vaccine construct to antigen processing cells(APCs). Moreover, the endogenously produced anti-DNP antibodies, together with the elicited antibodies against GM3-NHDNP, may synergistically promote tumor binding and cancer cell death when the cancer cell surfaces are glycoengineered to express the GM3-NHDNP antigen.展开更多
We report the design and development of aβ-glucuronidase(β-Glu)-responsive ManNAz derivative,Glu-AAM,for tumor-selective metabolic glycoengineering.Glu-AAM enables specific labeling of tumor cell surface sialoglycan...We report the design and development of aβ-glucuronidase(β-Glu)-responsive ManNAz derivative,Glu-AAM,for tumor-selective metabolic glycoengineering.Glu-AAM enables specific labeling of tumor cell surface sialoglycans in the presence of overexpressedβ-Glu in cancer cells,including breast,leukemia,and colorectal cancer cells.We demonstrate the high selectivity and efficiency of Glu-AAM-mediated metabolic glycoengineering across multiple cancer cell lines.Furthermore,we synthesized multivalent antibody-recruiting molecules(DBCO-Rha)that can be covalently attached to the azido-modified tumor cell surface,leading to potent antibody-dependent cellular phagocytosis and complement-dependent cytotoxicity.The octameric DBCO-Rha8 construct exhibited the most effective immune response.This integrated strategy ofβ-Glu-responsive metabolic glycoengineering and antibody-recruiting immunotherapy provides a promising platform for targeted cancer therapies and expands the toolbox of metabolic glycoengineering for cancer immunotherapy.展开更多
基金supported by the National Natural Science Foundation of China(No.22177040)the Natural Science Foundation of Jiangsu Province(No.BK20200601)partly funded by the 111 Project(No.111-2-06).
文摘Targeting delivery of tumor-associated carbohydrate antigen(TACA)-based vaccine to antigen-presenting cells(APCs)mediated by endogenous antibodies can improve the immunogenicity of TACA.However,an essential requirement of this approach is to generate high titers of endogenous antibodies in vivo through pre-immunization,which complicates the immunization procedure and may cause side effects.Herein,we report a new generation of APC-targeting TACA-based supramolecular complex vaccine,assembled by sialyl Thomsen-nouveau-bovine serum albumin-adamantine(sTn-BSA-Ada)and heptavalent rhamnose(Rha)-modifiedβ-cyclodextrin(β-CD)via host-vip interaction.The complex vaccine retained anti-Rha antibodies recruiting capability and facilitated the APCs uptake of the vaccine via the interaction of the Fc-domain with the Fc receptors on APCs.We demonstrate that direct immunization of complex vaccine elicited anti-Rha and anti-sTn specific immune response synchronously,generating a novel self-enhancement effect that can improve the antigen delivery to APCs in high efficacy.The structure-activity relationship(SAR)study proved that complex vaccine 4 with polyethylene glycol 6(PEG 6)linker in host molecule provoked a robust and specific sTn immune response comparable to the pre-immunization approach.The antisera induced by complex vaccine,either through direct immunization or pre-immunization,exhibited equal potency of cytotoxicity against the sTn expression cancer cells.This study provides a general platform for TACA-based vaccines with self-enhancement effects without the need for pre-immunization.
基金supported by the National Natural Science Foundation of China(Nos.21907038 and 32000904)Natural Science Foundation of Jiangsu Province(No.BK20200601)+5 种基金National Postdoctoral Program for Innovative Talents of China(No.BX20200153)China Postdoctoral Science Foundation(Nos.2018M632227 and2021M691293)the Social Development Key Project of Jiangsu Province(No.BE2019632)the Health and Family Planning Commission of Wuxi,China(No.Z202005)Suzhou People’s Livelihood Science and Technology Project,China(No.SYS2018100)supported by the 111 Project(No.111-2-06)。
文摘We construct MUC1 vaccines usingβ-cyclodextrin grafted chitosan(CS-g-CD)as carrier via host-vip interaction.These vaccines based on non-covalent assembling can provoke robust immune responses,including high level of specific antibodies and cytokines.The induced antibodies can specifically recognize tumor cells and mediate cytotoxicity against tumor cells.These results indicate that CS-g-CD with strong immunostimulatory activities can be a straightforward platform for peptide-based vaccine construction.
基金supported by the National Natural Science Foundation of China (Nos. 21472070 and 22177040)partly supported by the 111 Project (No. 111-2-06)。
文摘Staphylococcus aureus wall teichoic acids(WTAs) are attractive targets for antibacterial vaccine development. In this study, three core glycosylated WTA structure, including α-1,4-Glc NAc, β-1,4-Glc NAc andβ-1,3-Glc NAc modified ribitol phosphates containing a linker are chemically synthesized and conjugated with tetanus toxin(TT) carrier protein as vaccine candidates. In vivo immunological studies demonstrate that the synthesized glycosylated WTAs display high immunogenicity and all conjugates provoke strong immune responses and elicit high levels of specific IgG antibodies against the Glc NAc-modified WTA. Furthermore, antibodies elicited by the vaccine candidates remain the capability to recognize S. aureus cells and display significant opsonophagocytic activity to clear S. aureus. This study demonstrates that the core structure of glycosylated WTAs are effective antigens for constructing anti-S. aureus vaccines to prevent and control S. aureus infections.
基金supported by the National Natural Science Foundation of China (Nos. 21907038, 32000904)the Natural Science Foundation of Jiangsu Province (No. BK20200601, China)+4 种基金the National Postdoctoral Program for Innovative Talents of China (No. BX20200153)the Health and Family Planning Commission of Wuxi, China (No. Z202005)the Social Development Key Project of Jiangsu Province (No. BE2019632, China)partly supported by the 111 Project (No. 111-2-06, China)the National First-class Discipline Program of Food Science and Technology (No. JUFSTR20180101, China)。
文摘Tumor-associated carbohydrate antigens(TACAs) are attractive targets for vaccine development. In this context, we described a strategy combining artificial TACA and glycoengineering for cancer vaccine development. A 2,4-ditrophenyl(DNP)-modified GM3 intermediate was synthesized chemoenzymatically and conjugated to keyhole limpet hemocyanin(KLH), and the resulting bioconjugate was tested for its potential as a vaccine candidate. Mice immunological studies revealed that the DNP-modified GM3(GM3-NHDNP) analog elicited strong and rapid immune responses by recruiting anti-DNP antibodies to facilitate the targeted delivery of the vaccine construct to antigen processing cells(APCs). Moreover, the endogenously produced anti-DNP antibodies, together with the elicited antibodies against GM3-NHDNP, may synergistically promote tumor binding and cancer cell death when the cancer cell surfaces are glycoengineered to express the GM3-NHDNP antigen.
基金supported by the National Natural Science Foundation of China(No.22177040)partly funded by the Fundamental Research Funds for the Central Universities(No.JUSRP123037)the 111 Project(No.111-2-06).
文摘We report the design and development of aβ-glucuronidase(β-Glu)-responsive ManNAz derivative,Glu-AAM,for tumor-selective metabolic glycoengineering.Glu-AAM enables specific labeling of tumor cell surface sialoglycans in the presence of overexpressedβ-Glu in cancer cells,including breast,leukemia,and colorectal cancer cells.We demonstrate the high selectivity and efficiency of Glu-AAM-mediated metabolic glycoengineering across multiple cancer cell lines.Furthermore,we synthesized multivalent antibody-recruiting molecules(DBCO-Rha)that can be covalently attached to the azido-modified tumor cell surface,leading to potent antibody-dependent cellular phagocytosis and complement-dependent cytotoxicity.The octameric DBCO-Rha8 construct exhibited the most effective immune response.This integrated strategy ofβ-Glu-responsive metabolic glycoengineering and antibody-recruiting immunotherapy provides a promising platform for targeted cancer therapies and expands the toolbox of metabolic glycoengineering for cancer immunotherapy.
